Goldman Sachs analyst Salveen Richter maintained a Buy rating on Biogen (BIIB – Research Report) today. The company’s shares opened today at $301.02.
According to TipRanks, Richter is a 5-star analyst with an average return of 25.7% and a 51.54% success rate. Richter covers the Healthcare sector, focusing on stocks such as Biogen, Amgen, and Amicus.
In addition to Goldman Sachs, Biogen also received a Buy from Mizuho Securities’s Salim Syed in a report issued today. However, on May 23, Wedbush reiterated a Hold rating on Biogen (NASDAQ: BIIB).
See the top stocks recommended by analysts >>
BIIB market cap is currently $43.23B and has a P/E ratio of 13.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
Read More on BIIB:
- Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
- Fly Insider: Zions Bancorp, Albertsons among week’s notable insider trades
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Biogen says EC extends Tecfidera regulatory market protection to February 2025
- Biogen slips after competitor Eli Lilly’s Alzheimer’s trial hits target
